Difference between revisions of "Protein C, human (Ceprotin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 8: | Line 8: | ||
*'''Brand name:''' Ceprotin | *'''Brand name:''' Ceprotin | ||
| + | [[Category:Drugs]] | ||
[[Category:Fractionated plasma products]] | [[Category:Fractionated plasma products]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Revision as of 18:32, 24 March 2023
Human protein C
History of changes in EMA indication
- 7/16/2001: Initial authorization as Ceprotin
- CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.
Also known as
- Brand name: Ceprotin